Frontiers in Endocrinology (Aug 2022)

Gut microbiota: A new target for T2DM prevention and treatment

  • Lulu Liu,
  • Lulu Liu,
  • Jiheng Zhang,
  • Yi Cheng,
  • Meng Zhu,
  • Zhifeng Xiao,
  • Guangcong Ruan,
  • Yanling Wei

DOI
https://doi.org/10.3389/fendo.2022.958218
Journal volume & issue
Vol. 13

Abstract

Read online

Type 2 diabetes mellitus (T2DM), one of the fastest growing metabolic diseases, has been characterized by metabolic disorders including hyperglycemia, hyperlipidemia and insulin resistance (IR). In recent years, T2DM has become the fastest growing metabolic disease in the world. Studies have indicated that patients with T2DM are often associated with intestinal flora disorders and dysfunction involving multiple organs. Metabolites of the intestinal flora, such as bile acids (BAs), short-chain fatty acids (SCFAs) and amino acids (AAs)may influence to some extent the decreased insulin sensitivity associated with T2DM dysfunction and regulate metabolic as well as immune homeostasis. In this paper, we review the changes in the gut flora in T2DM and the mechanisms by which the gut microbiota modulates metabolites affecting T2DM, which may provide a basis for the early identification of T2DM-susceptible individuals and guide targeted interventions. Finally, we also highlight gut microecological therapeutic strategies focused on shaping the gut flora to inform the improvement of T2DM progression.

Keywords